drugset / Trial / NCT01760993
Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to determine if the long-term use of SPD489 (40, 80, 100, 120, 140, and 160mg) administered as a daily morning is safe and tolerable.
Timeline
- Start
- 2013-02-01
- Primary completion
- 2013-04-01
- Completion
- 2013-04-01
Outcome
Outcome not reported
Stopped (Business): “Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lisdexamfetamine Dimesylate | Small molecule | 40 mg | Oral |
| Subject | Lisdexamfetamine Dimesylate | Small molecule | 80 mg | Oral |
| Subject | Lisdexamfetamine Dimesylate | Small molecule | 100 mg | Oral |
| Subject | Lisdexamfetamine Dimesylate | Small molecule | 120 mg | Oral |
| Subject | Lisdexamfetamine Dimesylate | Small molecule | 140 mg | Oral |
| Subject | Lisdexamfetamine Dimesylate | Small molecule | 160 mg | Oral |